<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758026</url>
  </required_header>
  <id_info>
    <org_study_id>2018-21</org_study_id>
    <nct_id>NCT04758026</nct_id>
  </id_info>
  <brief_title>H&amp;N Cancer; Survivorship and Late Effects</brief_title>
  <official_title>Survivorship and Late Effects in Head and Neck Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cross-sectional study on late effects after modern treatment in long-term survivors of head&#xD;
      and neck cancer (HNC). Participants fill in questionnaires and participate at a one day visit&#xD;
      at the hospital including blood sample with biomarkers, clinical examination, audiometry,&#xD;
      oral radiological examination and oral examination. Data on patients' medical history&#xD;
      collected from medical records including radiology images and digital radiotherapy plans.This&#xD;
      will allow adjustments of treatment planning and improved treatment decisions for patients at&#xD;
      risk, and improve information and follow up for future patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to provide knowledge on late effects and mortality risk after&#xD;
      modern treatment in long-term survivors of head and neck cancer (HNC). This will allow&#xD;
      adjustments of treatment planning and improved treatment decisions for patients at risk, and&#xD;
      improve information and follow up for future patients. For head and neck cancer (HNC)&#xD;
      survivors of today, with the rising proportion of HPV induced cancer and with improved modern&#xD;
      treatment, the late effects and mortality risk has changed compared to survivors previous&#xD;
      decades.&#xD;
&#xD;
      The investigators will assess the prevalence and severity of a broad range of late effects&#xD;
      and identify associated risk factors for the following late effects;&#xD;
&#xD;
        -  Chronic fatigue&#xD;
&#xD;
        -  Hearing loss and tinnitus&#xD;
&#xD;
        -  Oral late effects, including taste and smell disturbances and osteoradionecrosis&#xD;
&#xD;
        -  Dysphagia and malnutrition&#xD;
&#xD;
        -  Body image, intimacy and endocrine dysfunction&#xD;
&#xD;
      In addition,possible biological explanatory mechanisms for fatigue and possibly other&#xD;
      selected late effects will be explored. Data will be compared to age and gender matched&#xD;
      reference data for those where this is available.&#xD;
&#xD;
      Design: a cross-sectional study&#xD;
&#xD;
      Assessments: Patient-reported questionnaires, blood sample with biomarkers, clinical&#xD;
      examination, audiometry, oral radiological examination and oral examination. Data on&#xD;
      patients' medical history collected from medical records including radiology images and&#xD;
      digital radiotherapy plans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">October 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of late effects after head and neck cancer treatment</measure>
    <time_frame>June 2022</time_frame>
    <description>Assess prevalence of fatigue, dysphagia, xerostomia, hearing problems, oral health, body image and intimacy in surivors of head and neck cancer more than 5 years after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for late effects after head and neck cancer treatement</measure>
    <time_frame>June 2022</time_frame>
    <description>to explore associated risk factors for fatigue, dysphagia, xerostomia, hearing problems, oral health in surivors of head and neck cancer more than 5 years after treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">265</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Survivorship</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample With biomarkers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HNC survivors treated at OUH in the period from 2006 to 2012 are eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically verified invasive carcinoma of the head and neck&#xD;
             region; ICD10: C01, C02.0 - C02.9; C03.0 - C03.9; C04.0 - C04.9; C05.0 - C05.9; C06.0&#xD;
             - C06.9; C07; C08.0 - C08.9; C09.0 - C09.9; C10.0 - C10.9; C11.0 - C11.9; C12; C13.0 -&#xD;
             C13.9; C14.0 - C14.9; C30; C31.0 - C31.9; C32.0 - C32.9, C77.0&#xD;
&#xD;
          -  Diagnosed 2006- 2012&#xD;
&#xD;
          -  Ability to understand and respond to the questionnaires&#xD;
&#xD;
          -  Ability to attend the clinical examination&#xD;
&#xD;
          -  Informed consent received&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to answer HRQL questionnaires&#xD;
&#xD;
          -  Patients under ongoing treatment for secondary cancer or relapse at the time of the&#xD;
             survey&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Cecilie Delphin Amdal</investigator_full_name>
    <investigator_title>Senior Oncologist, PhD, Researchgroupleader skin and head and neck cancer, Department of Oncology</investigator_title>
  </responsible_party>
  <keyword>Patient Reported Outcome Measure</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from 50-100 of the participants will be included in the EORTC 1629 - Late toxicity and long-term quality of life in head and neck cancer survivors</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>2020</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

